肿瘤预防与治疗2019，Vol.32Issue(7)：572-579,8.
复发转移性头颈部鳞癌的免疫治疗进展
Update in Immunotherapy for Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck
郭晔 1白春梅 2李志铭3
作者信息
- 1. 200120 上海,同济大学附属东方医院·上海市东方医院 肿瘤科
- 2. 100032 北京,北京协和医院 肿瘤内科
- 3. 510060 广州,中山大学肿瘤防治中心 肿瘤内科
- 折叠
摘要
Abstract
Squamous cell carcinoma of head and neck (SCCHN) is one of the common malignant tumors. Patients with recurrent or metastatic SCCHN have limited treatment options with limited efficacy. Tumor immunotherapy offers a new treatment option and hope for improved outcomes. Two programmed cell death-1 (PD-1) inhibitors, nivolumab and pem-brolizumab, have been approved for second-line treatment in patients with recurrent and metastatic SCCHN. Phase 2 and 3 clinical trials of the PD-1 pathway inhibitors demonstrated that the immune checkpoint inhibitors could improve survival outcome, with a sustained response and acceptable safety pro- file, and are gradually becoming one of the standards of care in patients with SCCHN who failed in platinum-based chemo-therapy.关键词
头颈部鳞癌/免疫治疗/程序性细胞死亡受体-1/程序性细胞死亡蛋白配体-1/纳武利尤单抗Key words
Squamous cell carcinoma of head and neck/Immunotherapy/Programmed cell death-1/Programmed cell death-1 ligand 1/Nivolumab分类
医药卫生引用本文复制引用
郭晔,白春梅,李志铭..复发转移性头颈部鳞癌的免疫治疗进展[J].肿瘤预防与治疗,2019,32(7):572-579,8.
